Advanced Proteome Therapeutics (TSXV:APC) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC’s Japanese Patent Application No. :2015-511804, titled “Site specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”. As quoted in the press release: “We are excited to announce the Japanese Patent Office …

Advanced Proteome Therapeutics (TSXV:APC) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC’s Japanese Patent Application No. :2015-511804, titled “Site specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.

As quoted in the press release:

“We are excited to announce the Japanese Patent Office has granted us this patent,” commented Randal Chase, CEO of Advanced Proteome Therapeutics. “This patent represents additional opportunities beyond just the North American market for advancing our relationships with the global biotech and pharmaceutical communities.”

Click here to read the full press release.

Featured
Amgen today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with ...

- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response (defined as an sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16.

In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of ≥ 4); affected body surface area (BSA) change from baseline; Dermatology Life Quality Index (DLQI) change from baseline; and static Physician's Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo.

read more Show less
Amgen today announced that the U.S. Food and Drug Administration has approved the expansion of the KYPROLIS ® U.S. prescribing information to include its use in combination with DARZALEX FASPRO ® and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. "I am pleased that the addition of subcutaneous daratumumab to KYPROLIS ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

"I am pleased that the addition of subcutaneous daratumumab to KYPROLIS plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden," said David M. Reese , M.D., executive vice president of Research and Development at Amgen.

read more Show less
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Bristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion Deadline: December 6, 2021 MISLEADING PROSPECTUS To ...

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://kclasslaw.com/cases/securities/nyse-bmy/

read more Show less

MARKETS

Markets
TSX20522.86-137.13
TSXV918.69-20.75
DOW34219.11-264.61
S&P 5004543.20-23.80
NASD15355.28-182.41
ASX7256.00+16.20

COMMODITIES

Commodities
Gold1779.72+6.34
Silver22.25-0.55
Copper4.22-0.06
Palladium1736.14-9.36
Platinum935.75-2.75
Oil65.45-0.73
Heating Oil2.07+0.01
Natural Gas4.25-0.32